Results 61 to 70 of about 24,588 (279)

Current Insights Into Individualized Diagnosis and Treatment of Allergic Rhinitis Based on Phenotype and Endotype

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Allergic rhinitis (AR) is a chronic inflammatory disease of the nasal mucosa characterized by allergen sensitization and the involvement of multiple inflammatory mediators. Currently, the treatment of AR mainly includes symptomatic relief, anti‐inflammatory therapy, and nerve desensitization. However, these treatments have limitations in fully
Yue Gu, Long‐Lan Shu, Tao Lu, Da‐Yu Guan, Bo‐Wen Zheng, Pan‐Hui Xiong, Yang Shen, Yu‐Cheng Yang   +7 more
wiley   +1 more source

Treatment of chronic urticaria with omalizumab: the experience of Hospital de Braga

Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2022
Introduction: Omalizumab is approved for the treatment of severe chronic spontaneous urticaria (CSU), unresponsive to quadruple doses of nonsedative H1 antihistamine.
Ana G. Lopes, Marianlie Navarro, Carmem Botelho, Maria J. Guimarães, Catarina Cerqueira, Joana Gomes, Celeste Brito   +6 more
doaj  

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients

Indian Dermatology Online Journal, 2016
Chronic spontaneous urticaria (CSU) affects 1% of the world population and also their quality of life, and 50% of these patients are refractory to H1-antihistamines.
Kiran Godse, Murlidhar Rajagopalan, Mukesh Girdhar, Sanjiv Kandhari, Bela Shah, Prashant N Chhajed, Sushil Tahiliani, D S Krupa Shankar, Vijay Somani, Vijay Zawar   +9 more
doaj   +1 more source

Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma [PDF]

, 2021
Jae‐Woo Jung, Hae‐Sim Park, Choon‐Sik Park, Sang‐Heon Cho, Inseon S. Choi, Hee‐Bom Moon, Soon Seog Kwon, Ho Joo Yoon, Jung‐Won Park, Jong‐Myung Lee, Dong‐Chull Choi, Byoung Whui Choi   +11 more
openalex   +1 more source

Integrative Analysis of Plasma Proteome and Genome Reveals Novel Drug Targets for Chronic Rhinosinusitis and Nasal Polyps

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) and nasal polyps (NP) are chronic inflammatory conditions with unsatisfactory treatment outcomes due to frequent recurrence of refractory disease. Identifying new therapeutic targets is essential. Methods We conducted a proteome‐wide Mendelian randomization (MR) analysis by integrating genome‐wide ...
En Zhou, Shi Luo, Yu Xiao, Bin Liu, Xu‐Ping Xiao   +4 more
wiley   +1 more source

Mepolizumab versus placebo for asthma [PDF]

, 2015
Background Mepolizumab is a human monoclonal antibody against interleukin-5 (IL-5), the main cytokine involved in the activation of eosinophils, which in turn causes airway inflammation.
Alvarez-Cuesta, Armentia, Ayars, Ayars, Ayres, Bel, Berger, Blanken, Blanken, Boever, Boulet, Bousquet, Bousquet, Braman, Brown, Bryant, Bryant, Buhl, Buhl, Buhl, Bush, Busse, Busse, Buttner, Caffarelli, Castro, Castro, Chandra, Chervinsky, Clavel, Corren, Corren, Cruz, Cullell-Young, Djukanovic, Ebner, Eckman, El-Nawawy, Fahy, Fahy, Finn, Flood-Page, Flood-Page, Flood-Page, Flood-Page, Frew, Fuhlbrigge, Garcia, Gauvreau, Gauvreau, Gauvreau, Gauvreau, Gevaert, Gibson, Gordon, Greenberg, Gupta, Haldar, Haldar, Haldar, Han, Hanania, Hanania, Hanania, Hill, Hodsman, Holgate, Hoshino, Humbert, Humbert, Humbert, Jacquemin, Jutel, Kandane-Rathnayake, Kang, Kay, Kips, Kon, Kopp, Kopp, Krishnan, Kulus, Lanier, Lanier, Laviolette, Leckie, Leynadier, Lizaso, Masoli, Massanari, Massanari, Mathur, Menzies-Gow, Menzies-Gow, Metzger, Milgrom, Milgrom, Modlin, Moss, Nair, Nair, Nair, Niven, Noga, Noga, Noonan, Oba, Oh, Ohashi, Ohman, Ohta, Ong, Ortega, Ortega, Parker, Patel, Pauli, Pavord, Pavord, Phipps, Piper, Prieto, Pui, Rensen, Rose, Sakamoto, Scheerens, Scheerens, Siergiejko, Silk, Silkoff, Simoes, Singh, Slavin, Soler, Sorkness, Sthoeger, Sugaya, Swanson, Szymaniak, Tanaka, Terr, Vignola, Wark, Wenzel, Wenzel, Wu, Zetterstrom, Zhu, Zielen   +149 more
core   +2 more sources

A Delphi Consensus on Clinical Features, Diagnosis, and Treatment of Chronic Rhinosinusitis With Nasal Polyps in the ASEAN Region

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) impacts patients' concentration, ability to work, and overall quality of life. Current treatment options include topical and oral medications, and surgery. Recent evidence supports the efficacy of biologics in improving symptoms and quality of life.
Baharudin Abdullah, Revadi Govindaraju, Salina Husain, Jin Keat Siow, Pongsakorn Tantilipikorn, Neville Wei Yang Teo, De Yun Wang, Deasi Anggraini, Tze Choong Charn, Chao‐Wu David Chin, Dichapong Kanjanawasee, Maung Maung Khaing, Jern‐Lin Leong, Luan Viet Tran, Harvinder Singh, Ing Ping Tang, Kim Thye Mark Thong, Gil M. Vicente, Yoke Yeow Yap, Soma Subramaniam   +19 more
wiley   +1 more source

OMALIZUMAB: EXPANDED OPPORTUNITIES FOR THE ATOPIC DISEASES TREATMENT

Педиатрическая фармакология, 2009
The review highlights experience and administration perspectives of the immunobiological medication Omalizumab in allergy. Omalizumab is the anti'IgE monoclonal antibody.
T.V. Kulichenko
doaj   +2 more sources

Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria

Future Science OA, 2020
Background: Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients
Laura Diluvio, Arianna Piccolo, Francesco Marasco, Laura Vollono, Caterina Lanna, Barbara Chiaramonte, Cinzia Niolu, Elena Campione, Luca Bianchi   +8 more
doaj   +1 more source

Astma ning selle ravi omalizumabiga: toime, ohutus ja kasutamine lastel [PDF]

, 2017
Bronhiaalastma on maailmas üks levinumaid haigusi, millele endiselt otsitakse tõhusamaid ravimeid. Kliinilises praktikas üle kümne aasta kasutatud immunoglobuliin E vastase monokloonse antikeha omalizumabi toime põhimõte on teada, kuid vaja on täpsustada,
Lääts, Liis
core   +2 more sources